Phase 2 N=20 Trial of Growth Hormone Therapy in Pediatric Crohn's Disease
Crohn's Disease
Primary: Crohn's Disease Histologic Index of Severity (CDHIS) — 7; 8; 6; 8 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=113 A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
Hypertension
Primary: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure — -0.3; -11.9; -15.3 mmHg
Phase 2 N=261 A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension
Hypertension
Primary: Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo. — -10.7; 1.8; -13.2…
Phase 2 N=54 Endermotherapy for Children With Developmental Disabilities
Cerebral Palsy · Developmental Delay
Primary: Ankle Passive Range of Motion — 8.3; 10.4 degree
Phase 2 N=155 A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentage of Participants With Serum Bactericidal Activity >=8 at 5 Years After Primary Vaccination — 30; 44; 11; 76 Percentage of participants
Phase 2 N=44 Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
Myocardial Infarction
Primary: Bleeding Time — 1020; 1020 seconds
Phase 2 N=817 Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects
Orthomyxoviridae Infection · Influenza · Myxovirus Infection
Primary: Number of Participants With at Least a 4-Fold Increase in Serum HAI Antibody Titer Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine…
Phase 2 N=36 Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas
Sarcoma
Primary: Number of Patients With Sarcoma Who Are Tumor Progression Free and Alive at Four Months From Start of Treatment With Single-agent Cetuximab. — 3; 1 participants — p=<0.05
Phase 2 N=90 A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
Chronic Idiopathic Urticaria
Primary: Change in Urticaria Activity Score 7 (UAS7) From Baseline to Week 4 — -6.91; -9.79; -19.93; -14.56 scores on a scale — p=0.1601
Phase 2 N=81 Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
Lymphoma, Large-Cell, Diffuse
Primary: Number of Participants With Objective Response — 9 participants
Phase 2 N=256 Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate
Rheumatoid Arthritis
Primary: Proportion of Patients Meeting American College of Rheumatology 20 Response Criteria (ACR20) at 12weeks — 60; 56; 54 percent meeting ACR 20 — p=0.982
Phase 2 N=246 To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
Type 2 Diabetes Mellitus · Impaired Glucose Tolerance
Primary: Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks. — -0.06; -0.23; 0.04; 0.45 pmol/min/m^2/mmol/L
Phase 2 N=51 Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
Metastatic Breast Cancer · Neoplasms, Breast
Primary: Clinical Benefit Response (Independent Reviewer-assessed) — 59 percentage of participants
Phase 2 N=25 Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
Carcinoma, Renal Cell
Primary: Time to Tumor Progression (TTP) Assessed Using Memorial Sloan-Kettering Cancer Center (MSKCC) Prognostic Factors Model — 3.1; 4.4; 8.0; 7.1 Months — p=0.860
Phase 2 N=16 The Use of Rosiglitazone to Treat Asthma
Asthma
Primary: Methacholine Responsiveness as Assessed by PC20, — 3.27; 8.71 mg/mL — p=0.048